First-Line Triplet in BRAF+ mCRC

An overview of the goals and design of the phase II single arm ANCHOR trial, which looks at the combination triplet regimen used in the BEACON study, encorafenib, binimetinib, and cetuximab, as first-line treatment for BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Related Videos
Dana B Cardin, MD, MSCI
In this fourth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, explains the implications of Lynch syndrome genotype on risk of colorectal cancer.
Dana B Cardin, MD, MSCI
Brian C. Grieb, MD, PhD
John L. Hays, MD, PhD
Brian C. Grieb, MD, PhD
Alaa Muslimani, MD
In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, discusses testing guidance for identifying Lynch syndrome.
Laura Goff, MD
Mariana X. Byndloss, DVM, PhD
Related Content

Liver Cancer Awareness Higher in Individuals Who Receive HBV/HCV Screening

May 26th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Research on Novel Targets and Potential Risk Factors Drives Improvements in the Management of GI Cancers

May 24th 2023

Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

May 24th 2023

Liver Cancer Awareness Higher in Individuals Who Receive HBV/HCV Screening

May 26th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Research on Novel Targets and Potential Risk Factors Drives Improvements in the Management of GI Cancers

May 24th 2023

Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

May 24th 2023

Liver Cancer Awareness Higher in Individuals Who Receive HBV/HCV Screening

May 26th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

May 25th 2023

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023

Research on Novel Targets and Potential Risk Factors Drives Improvements in the Management of GI Cancers

May 24th 2023

Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

May 24th 2023